

APR 28 2004

K040470
Page 1 of 2

SECTION 6 – 510(k) SUMMARY

[Submitted pursuant to 21 CFR 807.87(h)]

1. Submitter Information

Submitter: Direx Systems Corporation
11 Mercer Road
Natick Business Park
Natick, MA 01760

Telephone: (508) 651-0900
Fax: (508) 651-8125
Contact Person Larisa Gershtein
QA Manager

Contact Person e-mail address: lgershtein@direxusa.com

2. Device

Trade/Proprietary Name: Tripter X-1 Compact (to be marketed as
"Compact") w. Sonographic Localization
Option

Common/Usual Name: Extracorporeal Shock Wave Lithotripter
(ESWL)

Classification Name/ Product code: 78 LNS

Regulatory Class: Class II

Regulation Number: 21 CFR 876.5990

3. Predicate Devices

Tripter-X1 Series Lithotripters (Tripter-X1 and Tripter –X1 Compact): P-
920034

Tripter X1 Compact Duet: K023535

Ipu Rx-2 Image processing unit, Radiology K964327

Dornier CompactS / Compact Delta: P840008/S56

Dornier Compact Alpha: K002929 (and K011873)

SONOLITH 3000 PMA: P880011

K040470
page 2 of 2

4. Intended Use:

The intended use of the Tripter-X1 Compact Extracorporeal Shock Wave Lithotripter is the fragmentation of urinary tract stones (*i.e.* renal calyceal, renal pelvic, and upper ureteral stones).

5. Technological Characteristics:

This Compact includes a sonographic localization option that enables the use of ultrasound for positioning. The device has the same fundamental scientific technology and intended use as predicate devices.

6. Description

The *Compact* is a transportable Electrohydraulic Extracorporeal Shock Wave Lithotripter, which consists of a Shock Wave Generator (SWAG), a Motorized Floating Treatment Table (MFT), and control means.

7. Clinical Tests

No clinical tests were performed.

8. Conclusion

The Compact with the Sonographic Localization Option meets the requirements for a special 510(k) by the virtue of being a minor modification, which does not change the fundamental technology or reduce safety and effectiveness, of the Company's predicate device, the Tripter X-1 Compact.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 28 2004

Ms. Larisa Gershtein
QA Manager
DiREX Systems Corporation
11 Mercer Road
NATICK MA 01760

Re: K040470

Trade/Device Name: Tripter-X1 Compact
Regulation Number: 21 CFR §876.5990
Regulation Name: Extracorporeal shock wave lithotripter
Regulatory Class: II
Product Code: 78 LNS
Dated: April 1, 2004
Received: April 5, 2004

Dear Ms. Gershtein:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure



INTENDED USE STATEMENT

510(k) Number (if known): K040470

Device Name:

Tripter-X1 Compact

Intended Use:

The intended use of the Tripter-X1 Compact Extracorporeal Shock Wave Lithotripter is the fragmentation of urinary tract stones (i.e. renal calyceal, renal pelvic, and upper ureteral stones).

(PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF NEEDED)

510(k) Number K040470

Prescription Use ✓
(Per 21 CFR § 801.109)

OR

Over the Counter Use _____

A handwritten signature in black ink, appearing to read "David B. Seymour", is written over a horizontal line.

(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices

510(k) Number K040470